The prognostic value of postoperative radiotherapy in right tumor for lung related death: based on SEER database and real-world data.
IIIA-N2
lung laterality
non-small-cell lung cancer
overall survival
postoperative radiotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
02
03
2023
accepted:
16
03
2023
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Postoperative radiotherapy (PORT) is a therapeutic strategy for patients with non-small cell lung cancer (NSCLC). Nevertheless, some studies suggesting PORT does not improve overall survival (OS) including Lung ART phase III trial. The role of PORT and high-risk groups need to be confirmed. Patients from the Surveillance, Epidemiology, and End Results program (SEER) from 2004 to 2015 were eligible. Aged ≥18 years with stage IIIA-N2 NSCLC, accepted PORT or not were considered for the study. Cox regression analyses and multivariate competing risk model were performed. Propensity score matching (PSM) was conducted. Data from a single-center study in China were used for validation. In all patients with IIIA-N2 NSCLC, death from respiratory illness increased year by year, with right lung-related deaths accounting for the main proportion. In SEER database, PORT was detrimental for OS after PSM (hazard ratio [HR], 1.088; 95% CI, 1.088-1.174; PORT was a risk factor for stage IIIA-N2 NSCLC patients, particularly with characters of right laterality, male sex, age ≥65 years, and advanced tumor stage. These patients are more likely to death from lung disease after PORT.
Sections du résumé
Background
UNASSIGNED
Postoperative radiotherapy (PORT) is a therapeutic strategy for patients with non-small cell lung cancer (NSCLC). Nevertheless, some studies suggesting PORT does not improve overall survival (OS) including Lung ART phase III trial. The role of PORT and high-risk groups need to be confirmed.
Methods
UNASSIGNED
Patients from the Surveillance, Epidemiology, and End Results program (SEER) from 2004 to 2015 were eligible. Aged ≥18 years with stage IIIA-N2 NSCLC, accepted PORT or not were considered for the study. Cox regression analyses and multivariate competing risk model were performed. Propensity score matching (PSM) was conducted. Data from a single-center study in China were used for validation.
Results
UNASSIGNED
In all patients with IIIA-N2 NSCLC, death from respiratory illness increased year by year, with right lung-related deaths accounting for the main proportion. In SEER database, PORT was detrimental for OS after PSM (hazard ratio [HR], 1.088; 95% CI, 1.088-1.174;
Conclusions
UNASSIGNED
PORT was a risk factor for stage IIIA-N2 NSCLC patients, particularly with characters of right laterality, male sex, age ≥65 years, and advanced tumor stage. These patients are more likely to death from lung disease after PORT.
Identifiants
pubmed: 37091143
doi: 10.3389/fonc.2023.1178064
pmc: PMC10117832
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1178064Informations de copyright
Copyright © 2023 Mo, Chen, Wang, Wu and Yu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Natl Compr Canc Netw. 2020 Jun;18(6):718-727
pubmed: 32502986
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1442-57
pubmed: 20934273
J Clin Oncol. 2015 Mar 10;33(8):870-6
pubmed: 25667283
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Int J Cardiol. 2021 May 1;330:186-193
pubmed: 33581175
Lung. 2008 Mar-Apr;186(2):91-6
pubmed: 18097718
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32929052
Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):1055-66
pubmed: 9276372
Ann Surg Oncol. 2021 Jan;28(1):142-147
pubmed: 32951092
Lancet. 1998 Jul 25;352(9124):257-63
pubmed: 9690404
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1097-105
pubmed: 16682136
Br J Cancer. 2020 Dec;123(Suppl 1):1-2
pubmed: 33293669
J Natl Compr Canc Netw. 2019 Dec;17(12):1464-1472
pubmed: 31805526
JAMA Oncol. 2021 Aug 01;7(8):1178-1185
pubmed: 34165501
Strahlenther Onkol. 2002 Apr;178(4):199-208
pubmed: 12040757
J Thorac Oncol. 2016 Sep;11(9):1538-49
pubmed: 27374454
Radiother Oncol. 2014 Jan;110(1):3-8
pubmed: 24100149
Eur J Cancer. 2017 Nov;85:106-113
pubmed: 28898766
Front Oncol. 2020 Dec 23;10:594590
pubmed: 33425746
Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):492-9
pubmed: 16814952
Cancer Med. 2020 Apr;9(8):2820-2832
pubmed: 32100444
BMJ. 2003 Feb 1;326(7383):256-7
pubmed: 12560277
J Clin Oncol. 2001 Oct 1;19(19):3912-7
pubmed: 11579111
Cancer. 2007 Aug 15;110(4):911-7
pubmed: 17620279